- Home
- IDYA vs FCPT Comparison
IDYA vs FCPT Comparison
Compare IDYA & FCPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- FCPT
- Stock Information
- Founded
- IDYA 2015
- FCPT 2015
- Country
- IDYA United States
- FCPT United States
- Employees
- IDYA N/A
- FCPT N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- FCPT Real Estate Investment Trusts
- Sector
- IDYA Health Care
- FCPT Real Estate
- Exchange
- IDYA Nasdaq
- FCPT Nasdaq
- Market Cap
- IDYA 2.3B
- FCPT 2.7B
- IPO Year
- IDYA 2019
- FCPT N/A
- Fundamental
- Price
- IDYA $24.44
- FCPT $25.41
- Analyst Decision
- IDYA Buy
- FCPT Buy
- Analyst Count
- IDYA 14
- FCPT 6
- Target Price
- IDYA $47.75
- FCPT $29.60
- AVG Volume (30 Days)
- IDYA 1.2M
- FCPT 535.5K
- Earning Date
- IDYA 11-03-2025
- FCPT 10-29-2025
- Dividend Yield
- IDYA N/A
- FCPT 5.58%
- EPS Growth
- IDYA N/A
- FCPT 1.85
- EPS
- IDYA N/A
- FCPT 1.08
- Revenue
- IDYA $7,000,000.00
- FCPT $279,445,000.00
- Revenue This Year
- IDYA $62.30
- FCPT $9.18
- Revenue Next Year
- IDYA $285.58
- FCPT $7.31
- P/E Ratio
- IDYA N/A
- FCPT $23.55
- Revenue Growth
- IDYA N/A
- FCPT 6.29
- 52 Week Low
- IDYA $13.45
- FCPT $25.01
- 52 Week High
- IDYA $37.19
- FCPT $30.93
- Technical
- Relative Strength Index (RSI)
- IDYA 49.04
- FCPT 42.84
- Support Level
- IDYA $24.24
- FCPT $25.26
- Resistance Level
- IDYA $25.49
- FCPT $25.82
- Average True Range (ATR)
- IDYA 1.35
- FCPT 0.37
- MACD
- IDYA -0.15
- FCPT -0.03
- Stochastic Oscillator
- IDYA 27.13
- FCPT 13.16
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About FCPT Four Corners Property Trust Inc.
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.